Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug

After turning around Celgene’s S1P modulator for a long-awaited approval in multiple sclerosis, Bristol Myers Squibb is now trading in an FDA wildcard to get a quick review in ulcerative colitis.

BMS has redeemed a priority review voucher for a speedy decision on its supplemental NDA for Zeposia, which hit the market this past June for MS. The FDA set a PDUFA date for May 30 — and if given the thumbs up, BMS says it would have the first oral sphingosine-1-phosphate (S1P) receptor modulator for UC.